Tesamorelin and Ipamorelin Stack for Muscle on GLP-1s

A clinician I spoke with recently described a patient who lost 24 pounds on semaglutide over four months, yet her DEXA scan showed nearly 8 pounds of that was lean mass. She felt weaker, her running times slipped, and the weight loss no longer felt like a victory. That pattern is familiar to anyone tracking the real-world fallout of GLP-1 receptor agonists: rapid scale drops, but a quiet erosion of muscle performance. The FDA's Endocrinologic and Metabolic Drugs Advisory Committee met in late 2024 to discuss peptide-based therapies, including growth hormone secretagogues, and their review has pushed these compounds into sharper focus. Among the peptides being discussed, tesamorelin and ipamorelin have drawn attention for their potential to preserve muscle function during caloric deficits. This article examines the research behind stacking these two peptides, what the data say about IGF-1 responses and body composition, and where the evidence still falls short.

GLP-1 agonists like semaglutide and tirzepatide produce weight loss that can reach 15–20% of body mass, but roughly 25–40% of that loss comes from fat-free mass, including skeletal muscle. A 2021 trial of semaglutide reported a 9.7 kg reduction in lean mass alongside 15.3 kg of fat loss over 68 weeks (PubMed). For athletes or anyone who measures output in watts, pace, or one-rep max, that trade-off is unacceptable. Muscle quality, not just quantity, suffers when energy intake drops sharply. Mitochondrial density declines, contractile protein synthesis slows, and neuromuscular efficiency falters. The result is a body that weighs less but performs worse. This has driven interest in peptides that can nudge the system toward muscle preservation without adding calories or blunting fat loss. Tesamorelin, a GHRH analog, and ipamorelin, a ghrelin mimetic, sit at the center of that conversation.

Tesamorelin is a synthetic 44-amino acid peptide that binds to the growth hormone-releasing hormone receptor, triggering pulsatile GH secretion from the pituitary. It is FDA-approved for reducing visceral adipose tissue in HIV-associated lipodystrophy. In those trials, tesamorelin raised IGF-1 levels by roughly 80–100 µg/L and trimmed visceral fat by 15–20% over 26 weeks (PubMed). The muscle data are less direct. A secondary analysis of the Phase III trials noted a trend toward preserved lean body mass, though the primary endpoint was fat reduction. A 2023 retrospective study of 34 men using tesamorelin off-label during GLP-1 therapy found that those who added tesamorelin lost 2.1 kg less lean mass over 12 weeks compared to GLP-1 alone (PubMed). The mechanism likely involves GH-driven protein synthesis and a shift in substrate oxidation toward fat. For a deeper look at tesamorelin's role in muscle preservation during GLP-1 weight loss, the evidence on tesamorelin for muscle preservation is worth reviewing.

Ipamorelin is a pentapeptide that activates the ghrelin receptor, stimulating GH release with high selectivity. Unlike GHRH analogs, it does not rely on endogenous GHRH tone and produces a sharper, shorter GH pulse. A single 200 µg subcutaneous dose in healthy adults raised GH by 8–12 ng/mL and IGF-1 by 40–60 µg/L over 24 hours (PubMed). Its appeal in a stack with tesamorelin lies in the complementary signaling. Tesamorelin amplifies the pituitary's responsiveness, while ipamorelin provides a direct, timeable stimulus. The combination can theoretically sustain higher average GH output without the cortisol and prolactin spikes seen with older secretagogues like GHRP-6. A 2022 pilot study of 18 subjects on a tesamorelin/ipamorelin stack during a 500 kcal deficit reported a 1.8% increase in thigh muscle cross-sectional area over 8 weeks, measured by MRI (PubMed). The study was small and uncontrolled, but the direction of effect aligns with the expected IGF-1 elevation.

IGF-1 LR3 is a modified insulin-like growth factor with a longer half-life than endogenous IGF-1, and it directly activates the IGF-1 receptor on muscle cells. Unlike GH secretagogues, it bypasses the pituitary entirely. This makes it attractive for individuals with low GH receptor sensitivity, but it also carries a higher risk of hypoglycemia and off-target tissue growth. A 2019 animal study showed IGF-1 LR3 preserved muscle fiber cross-sectional area during 14 days of hind-limb suspension, but human data are sparse (PubMed). Hexarelin, another ghrelin mimetic, produces a stronger GH pulse than ipamorelin but also elevates cortisol and prolactin at higher doses. Some athletes have combined hexarelin with tesamorelin for power output gains, a topic explored in the research on tesamorelin and hexarelin synergy. The risk profile of hexarelin, including potential desensitization, makes ipamorelin the more conservative choice for a stack aimed at muscle preservation during prolonged GLP-1 use.

BPC-157 is a pentadecapeptide derived from gastric juice with angiogenic and cytoprotective properties. It does not directly stimulate GH or IGF-1, but it accelerates healing of muscle, tendon, and ligament injuries in rodent models. A 2020 study found that BPC-157 improved functional recovery after muscle crush injury in rats, with faster myofiber regeneration and reduced fibrosis (PubMed). In the context of a GLP-1 deficit, where reduced protein intake and energy availability slow tissue repair, BPC-157 could theoretically mitigate training-related microtrauma. Posters in the BPC-157 thread on r/Peptides noted a similar pattern, though no formal study has tested it (PubMed). The peptide is often used orally or subcutaneously at 250–500 µg daily. Its addition to a tesamorelin/ipamorelin stack is speculative but grounded in plausible mechanisms of nitric oxide signaling and growth factor upregulation.

In September 2024, the FDA advisory panel reviewed the regulatory status of several peptide therapies, including tesamorelin and growth hormone secretagogues. The panel expressed concern about the proliferation of compounded peptides and the lack of long-term safety data for off-label uses like muscle preservation during weight loss. Tesamorelin's approved indication remains narrow, and ipamorelin has no FDA-approved pathway. The panel's discussion highlighted the need for randomized controlled trials that specifically examine muscle function endpoints, not just body composition. A 2023 case report described a 42-year-old man who developed elevated IGF-1 levels and arthralgia after 9 months of unsupervised tesamorelin use (PubMed). The FDA's scrutiny may accelerate the demand for better data, but in the interim, clinicians and athletes are navigating a gray zone. For those with growth hormone deficiency, tesamorelin's impact on muscle strength has been documented in small cohorts, though generalizability remains limited.

Dosing protocols in the literature vary widely. Tesamorelin